TimmermanReport - Where Did You Go First?

At Takeda, Timmerman worked in business development. He left to start a biotech company from scratch called obsidian therapeutics. The idea was that by applying small molecule control elements to the transgene you put in CAR-T or really any gene therapy, you could actually control the activity of the cell product in the patient. "This sounds super cool," he says.